However, despite the contrasting ideas on miRNA-based therapy, the majority of the studies demonstrate that miR-205 plays an oncosuppressive role in breast cancer, acting both on neoplastic cells and tumor microenvironment, and its re-introduction in tumors might be exploited to counteract tumor growth and to improve responsiveness to breast cancer therapies, mainly anti-HER2 treatments. This evidence concerns the gene ERBB2 and breast cancer.